Boston Scientific Corp (BSX) revenue by segment
BSXNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 14/3048% below fair value
$43.64+0.61 (+1.42%)
Close on Nov 18, 2026Market cap $63.24BP/E 17.7Yield –
Doanh thu theo bộ phận của Boston Scientific Corp
Theo bộ phận kinh doanh
| Doanh thu | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % doanh thu | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular | $13.25B | $10.76B | $8.82B | $7.83B | $7.24B | $5.87B | $4.21B | $3.78B | $3.50B | $3.29B | 66.0% | +23.2% |
| MedSurg | $6.82B | $5.99B | $5.42B | $4.91B | $4.63B | $3.83B | $3.31B | $3.01B | $2.74B | $2.45B | 34.0% | +13.9% |
| BSX Reportable Segments | – | – | – | – | $11.88B | $9.69B | $10.65B | $9.82B | $9.05B | – | – | – |
| Rhythm and Neuro | – | – | – | – | $3.29B | $2.75B | $3.14B | $3.04B | $2.81B | $2.65B | – | – |
| Other Segments | – | – | – | – | – | – | $81.00M | – | – | – | – | – |
| Rhythm Management | – | – | – | – | – | – | – | – | $2.17B | $2.09B | – | – |
| Global Urology (Uro) Reporting Unit | – | – | – | – | – | – | – | – | – | $1.07B | – | – |
| Neuromodulation | – | – | – | – | – | – | – | – | – | $574.00M | – | – |
| Global CRM Reporting Unit | – | – | – | – | – | – | – | – | – | $1.99B | – | – |
| Global Interventional Cardiology (IC) Reporting Unit | – | – | – | – | – | – | – | – | – | $2.52B | – | – |
| Global Electrophysiology (EP) Reporting Unit | – | – | – | – | – | – | – | – | – | $261.00M | – | – |
| Endoscopy | – | – | – | – | – | – | – | – | – | $1.57B | – | – |
| Peripheral Interventions | – | – | – | – | – | – | – | – | – | $1.09B | – | – |
| Lợi nhuận hoạt động | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular | – | – | – | – | – | – | $1.14B | $1.12B | $988.00M | $946.00M | – |
| MedSurg | – | – | – | – | – | – | $1.20B | $1.10B | $984.00M | $852.00M | – |
| Total allocated to reportable segments | – | – | – | $3.74B | $3.41B | $2.20B | $3.01B | $2.88B | $2.51B | $2.20B | – |
| Other | – | – | – | -$60.00M | $4.00M | $143.00M | – | – | – | – | – |
| Specialty Pharmaceuticals | – | – | – | – | $4.00M | $143.00M | $56.00M | – | – | – | – |
| Rhythm and Neuro | – | – | – | – | – | – | $666.00M | $655.00M | $537.00M | $402.00M | – |
| Rhythm Management | – | – | – | – | – | – | – | – | $429.00M | $314.00M | – |
Theo sản phẩm hoặc dịch vụ
| Doanh thu | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % doanh thu | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interventional Cardiology & Vascular Therapies | $4.64B | $2.65B | $2.42B | $2.23B | $2.21B | $1.98B | – | – | – | – | 23.1% | +75.4% |
| Electrophysiology | $3.33B | $1.90B | $800.00M | $585.00M | $365.00M | $287.00M | – | – | – | – | 16.6% | +74.6% |
| Endoscopy | $2.92B | $2.69B | $2.48B | $2.22B | $2.14B | $1.78B | $1.89B | $1.76B | $1.62B | $1.44B | 14.5% | +8.5% |
| Urology | $2.71B | $2.20B | $1.96B | $1.77B | $1.58B | $1.29B | $1.41B | $1.25B | $1.12B | $1.01B | 13.5% | +23.1% |
| Cardiac Rhythm Management | $2.33B | $2.28B | $2.22B | $2.10B | $2.02B | $1.70B | – | – | – | – | 11.6% | +2.3% |
| Watchman | $1.96B | $1.52B | $1.27B | $1.02B | $829.00M | $324.00M | – | – | – | – | 9.8% | +29.2% |
| Neuromodulation | $1.20B | $1.11B | $976.00M | $917.00M | $909.00M | $761.00M | $873.00M | $779.00M | $635.00M | $556.00M | 6.0% | +8.4% |
| Interventional Oncology & Embolization | $996.00M | $856.00M | $736.00M | – | – | – | – | – | – | – | 5.0% | +16.4% |
| Peripheral Interventions | – | $2.41B | $2.11B | $1.90B | $1.82B | $1.58B | $1.39B | $1.19B | $1.08B | $1.01B | – | – |
| Cardiology | – | $8.34B | $6.71B | $5.93B | $5.42B | $4.29B | – | – | – | – | – | – |
| Other | – | $0 | $0 | -$60.00M | $13.00M | $219.00M | – | – | – | – | – | – |
| Specialty Pharmaceuticals | – | – | – | – | $13.00M | $219.00M | $81.00M | – | – | – | – | – |
| Global Interventional Cardiology (IC) Reporting Unit | – | – | – | – | $3.04B | $2.30B | $2.82B | $2.59B | $2.42B | $2.28B | – | – |
| Global Electrophysiology (EP) Reporting Unit | – | – | – | – | $365.00M | $287.00M | $329.00M | $311.00M | $278.00M | $243.00M | – | – |
| Global CRM Reporting Unit | – | – | – | – | $2.02B | $1.70B | $1.94B | $1.95B | $1.90B | $1.85B | – | – |
| BTG Spec Pharma | – | – | – | – | – | – | $81.00M | – | – | – | – | – |
Theo khu vực
| Doanh thu | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % doanh thu | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $12.86B | $10.21B | $8.43B | $7.63B | $6.91B | $5.70B | $6.17B | $5.54B | $5.16B | $4.76B | 64.1% | +26.0% |
| Int'l | $7.21B | $6.54B | $5.82B | $5.11B | $4.98B | $4.21B | $4.57B | $4.29B | $3.89B | $3.63B | 35.9% | +10.3% |
| Europe, Middle East and Africa | $3.45B | $3.23B | $2.86B | $2.53B | $2.52B | $2.10B | $2.26B | $2.18B | $1.94B | $1.80B | 17.2% | +6.9% |
| Asia-Pacific | $3.08B | $2.69B | $2.40B | $2.12B | $2.07B | $1.78B | $1.90B | $1.73B | $1.59B | $1.49B | 15.3% | +14.7% |
| Emerging Markets | $2.99B | $2.68B | $2.31B | $1.97B | $1.66B | $1.14B | $1.28B | $1.10B | $931.00M | $793.00M | 14.9% | +11.4% |
| Latin America and Canada | $678.00M | $624.00M | $560.00M | $469.00M | $386.00M | $307.00M | $395.00M | $383.00M | $358.00M | $333.00M | 3.4% | +8.7% |
| country_US excluding Other Net Sales | – | $10.21B | $8.43B | $7.63B | $6.90B | $5.51B | – | – | – | – | – | – |
Lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K, 10-Q của Boston Scientific (XBRL). Số quý 4 bằng cả năm tài chính trừ chín tháng đầu. Tên bộ phận giữ theo cách công ty tự đặt và có thể đổi khi công ty tái cấu trúc. Tab KPI hiện các bộ phận này cạnh chỉ số vận hành của Boston Scientific, kèm đầy đủ lịch sử, biểu đồ và liên kết tới từng hồ sơ.
See a number that looks wrong?